Current Scheduling Status
Schedule I and Schedule IV of the 1961 Convention on Narcotic Drugs
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
Substance identification
PEPAP (CAS 64-52-8); chemical name: (1) CAS: 4-phenyl-1-(2-phenylethy!)-4-piperidinol acetate (ester); (2) IUFA: 1-phenylethyl-4-phenyl-4-acetoxy-piperidine. No isomers are possible.
Similarity to known substances and effects on the CNS
PEPAP has- been classified pharmacologically as an agonist of mu-type opioid receptors with a profile similar to-that of pethidine. It possesses analgesic activity and produces morphine-like euphoric effects. Its analgesic potency is about twice that of morphine. Like other mu-type opioids, PEPAP depresses respiration and its. effects on the central. nervous system
can be reversed by narcotic antagonists such as naloxone.
Dependence potential
PEPAP substitutes completely for morphine i m morphine: dependent monkeys.
Actual abuse and or/evidence of likelihood of abuse
Seizure of a clandestine laboratory. and confiscation of numerous street samples containing PEPAP have been reported by the USA. PEPAP is controlled asa narcotic substance in France and the USA.
Therapeutic usefulness
At present, PEPAP has no Known therapeutic use.
Recommendation
The Committee found that there was sufficient evidence to indicate that PEPAP is liable to similar abuse as, and produces ill effects similar to those seen with, drugs in Schedule I of the Single Convention on Narcotic Drugs, 1961 and that Convention as amended by the 1972 Protocol. The Committee rated the abuse liability of the.drug as high. The degree of seriousness
of the public health and social problems associated with the drug was found to be high, and there is no known therapeutic use. Therefore, the Committee recommended that PEPAP be
controlled in Schedules I and IV of the Single Convention on Narcotic Drugs, 1961 and that Convention. as amended by the 1972 Protocol.
PEPAP (CAS 64-52-8); chemical name: (1) CAS: 4-phenyl-1-(2-phenylethy!)-4-piperidinol acetate (ester); (2) IUFA: 1-phenylethyl-4-phenyl-4-acetoxy-piperidine. No isomers are possible.
Similarity to known substances and effects on the CNS
PEPAP has- been classified pharmacologically as an agonist of mu-type opioid receptors with a profile similar to-that of pethidine. It possesses analgesic activity and produces morphine-like euphoric effects. Its analgesic potency is about twice that of morphine. Like other mu-type opioids, PEPAP depresses respiration and its. effects on the central. nervous system
can be reversed by narcotic antagonists such as naloxone.
Dependence potential
PEPAP substitutes completely for morphine i m morphine: dependent monkeys.
Actual abuse and or/evidence of likelihood of abuse
Seizure of a clandestine laboratory. and confiscation of numerous street samples containing PEPAP have been reported by the USA. PEPAP is controlled asa narcotic substance in France and the USA.
Therapeutic usefulness
At present, PEPAP has no Known therapeutic use.
Recommendation
The Committee found that there was sufficient evidence to indicate that PEPAP is liable to similar abuse as, and produces ill effects similar to those seen with, drugs in Schedule I of the Single Convention on Narcotic Drugs, 1961 and that Convention as amended by the 1972 Protocol. The Committee rated the abuse liability of the.drug as high. The degree of seriousness
of the public health and social problems associated with the drug was found to be high, and there is no known therapeutic use. Therefore, the Committee recommended that PEPAP be
controlled in Schedules I and IV of the Single Convention on Narcotic Drugs, 1961 and that Convention. as amended by the 1972 Protocol.
ECDD Recommendation
Inclusion in Schedule I and Schedule IV of the 1961 Convention on Narcotic Drugs
Link to full TRS
who_trs_761.pdf1.41 MB